Cardiac Arrest (CA)NCT07875348
Integrated Near-Infrared Spectroscopy and Hemodynamic Monitoring for Cerebral Autoregulation in Post-Cardiac Arrest Care Neuroprognostication
An observational study of Cardiac Arrest (CA), run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Neurological outcome is the primary outcome for post-cardiac arrest patients. Hypoxic-ischemic brain injury is a key element in post-cardiac arrest syndrome, and remains the leading cause of mortality and morbidity in post-cardiac arrest patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Arrest (CA)
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- Jan 2027to 31 Dec 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: post-cardiac arrest patients admitted to ICU
Who may be able to join
- non-traumatic cardiac arrest
- admitted to ICU
- unable to follow verbal instructions (GCS: motor <=5)
Who cannot join
- traumatic cardiac arrest
- pregnancy
- cognitive impairment before cardiac arrest (CPC scale >=3)
- severe peripheral artery diseases
- Raynaud's syndrome
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site
National Taiwan University Hospital
Taipei
Dean-An Ling, MD, +886-02-23123456, speckle0714@gmail.com
About this study
Neurological outcome is the primary outcome for post-cardiac arrest patients. Hypoxic-ischemic brain injury is a key element in post-cardiac arrest syndrome, and remains the leading cause of mortality and morbidity in post-cardiac arrest patients. In patients with hypoxic-ischemic brain injury, impaired cerebral autoregulation makes cerebral blood flow highly vulnerable to blood pressure fluctuations, which might trigger secondary brain injuries. Although the pressure reactivity index (PRx) calculated via invasive intracranial pressure (ICP) monitoring is considered the gold standard for assessing cerebral autoregulation, its clinical application in post-cardiac arrest patients is limited due to invasive risks. Alternatively, cerebral near-infrared spectroscopy (NIRS) combined with hemodynamic monitoring offers a non-invasive approach to measure the cerebral oxygenation index (COx). However, its consistency with invasive methods and its accuracy in post-cardiac arrest care warrant further validation. The aim of this study is to assess cerebral autoregulation via COx calculated with NIRS and hemodynamic parameters in post-cardiac arrest patients, and to analyze the impact of this index on neurological outcomes. The further goal is to estimate optimal mean arterial pressure (MAPopt) and subsequently establish personalized post-resuscitation blood pressure targets.
- Conditions
- Cardiac Arrest (CA)
- Medical subject headings
- Heart Arrest
What is being measured
The primary outcome is the main question the study is designed to answer.
Neurological Outcome
Cerebral Performance Category Scale (1-5), higher scores mean a worse outcome
Measured: up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2026
- Study startJan 2027 (estimated)
- Primary completion31 Jul 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Arrest (CA)Studies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dean-An Ling, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07875348
- Sponsor's protocol ID
- 202606297RINA
- Status last verified
- Oct 2026
- First submitted
- 5 Oct 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No